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Abstract 
Yue Chen, PhD 
The Oral Microbiome and Subclinical Herpesvirus Shedding in HIV Infected Men on ART 
Kendal Everett Fike, MPH 
 
University of Pittsburgh, 2019 
 
 
 
Abstract 
 
Despite undetectable plasma HIV load and CD4 counts reconstitution due to the effective 
Antiretroviral Therapy (ART) people living with HIV (PWH) are still at a higher risk for 
developing non-AIDS-associated chronic diseases, which have been linked to systemic immune 
activation and inflammation. Human microbiota composed of bacteria, viruses and fungi plays 
an important role in the induction and function of the host immune system and the symbiosis and 
dysbiosis of fecal and/or oral microbiome have both the local and systemic effects on the 
immune system. We hypothesize that oral microbiome dysbiosis of PWH leads to systemic 
immune activation and contributes to non-AIDS-associated chronic diseases. The objective of 
this study was to evaluate whether the oral microbiome of PWH on ART is associated with 
levels of systemic immune activation and oral herpesvirus shedding. Thirteen HIV-infected 
participants on ART and 11 age matched HIV-negative controls participated in this study. Two 
oral samples with 6-month intervals were collected from each participant. The DNA was isolated 
from the samples, and the 16S rRNA V4 region was amplified of the DNA by PCR followed by 
sequencing using Illumina MiSeq platform. The sequence data were analyzed using Qiime2 and 
statistical analysis was performed by Stata. The results show there were no statistically 
significant differences in alpha diversity and beta diversity of oral bacteria at family level 
between PWH on ART and negative controls at both week 0 and week 24 time points, 
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respectively. There are also no significant correlations between alpha diversity of oral bacteria 
and plasma inflammatory cytokine levels generated from the previous study. However, when the 
data were analyzed with herpesvirus shedding, which was obtained from a previous study using 
the same oral samples, alpha diversity of oral bacteria was significantly decreased in participants 
with HHV6 shedding compared to those who had no HHV6 shedding regardless of HIV status. 
In addition, the beta diversity of oral bacteria is also significantly different based on HHV6 
shedding status in these oral samples. The same phenomena were not observed based on EBV, 
CMV or HHV8 shedding status. Our results suggest there may be intricate interplays in the oral 
microbiome. Future studies with a larger number of participants in each group are needed to 
determine the role of the oral microbiome in the systemic immune activation observed in PWH 
on ART. Among PWH on ART, a significant public health concern exists regarding the role of 
oral microbiome effect on immune activation. There is an imperative need for research to lead to 
a better treatment strategy concerning non-AIDS chronic diseases in this population. 
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1.0 Introduction 
Human microbiome dysbiosis, defined as “a state of community disturbance” is a major 
cause of microbiome-related systemic diseases.[41] The human oral cavity is the primary 
gateway to the acquisition of great numbers of bacteria defined as the human oral microbiome. 
An oral infection caused by a range of microorganisms can lead to system infections such as 
cardiovascular disease, diabetes mellitus, rheumatoid arthritis, and Alzheimer’s disease.[41] The 
human oral microbiomes also exert influence on other body functions such as the immune 
system and physiological functions.[41]  
In addition, using 16S rRNA gene based techniques it is estimated that there are between 
500-700 bacteria species in the human mouth, and there are no significant differences in 
microbiome communities based on gender, age, and race.[4]  
Human mucosal tissue is the most common route of HIV transmission, but which rarely 
occurs from oral mucosa.[19] However, compared to HIV negative counterparts, PWH are more 
likely to have other oral infections including the herpesvirus even when they are receiving 
antiretroviral therapy (ART).[19] The oral dysbiosis in PWH is hypothesized to impact other 
parts of the body through immune activation causing systemic inflammation. The oral cavity is 
continuously exposed to external stimuli, which can introduce the infectious agents to the mouth 
and the entire body.[19]  
The purpose of this thesis is to examine the relationship between the oral microbiome and 
HIV associated immune activation and herpesvirus shedding status. 
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1.1 HIV pathogenesis and treatment 
HIV infection proceeds in three distinct stages: acute infection, clinical latency, and 
AIDS.[32] Acute HIV infection begins within two to four weeks post HIV transmission. 
Individuals may present with flu-like symptoms, but up to half of infected individuals may not 
present classical symptoms during acute infection. During this phase, many copies of the virus 
are being produced in the infected individuals. When the virus is replicating, host CD4+ T-cells 
are slowly being destroyed, which compromises the host’s immune system.[32] In the chronic 
infection stage the virus continues to replicate in blood and lymph nodes of the host.[32] The 
final stage of HIV infection is the progression to AIDS, which occurs at a median of 8 years 
from infection if the individual is not on ART. A key component of AIDS is defined by the 
increased risk of developing opportunistic infections (OI) due to the severely compromised 
immune system. Individuals can become virally suppressed at any stage of infection by 
administration of antiretroviral treatment (ART). PWH may not progress to AIDS if viral 
suppression is achieved through the use of ART.[30] 
The current and most effective approach for the treatment of PWH is suppression of viral 
replication through ART. The majority of PWH receive a combination of antiviral drugs. The 
goal of this treatment is to provide a potent enough ART to prevent viral replication and drug 
resistance by reducing plasma viremia to below the limit of detection of commercial assays.[30] 
The immune function often recovers rates of and AIDS-related clinical diseases sharply 
decrease. The negative aspect of current ART includes the high cost of medications and care, the 
need for lifelong therapy, and the emergence of drug resistant HIV if there is incomplete 
adherence to the medication. There are also concerns of long-term toxic effects of small-
molecule drugs. However, although ART is very effective, PWH still have a high prevalence of 
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non-AIDS chronic diseases, which is believed to be due to immune activation and chronic 
inflammation. 
1.2 HIV pathogenesis and microbiome 
Microbiome or small biome is an ecosystem in which all microorganisms that exist in a 
particular environment constitute a comprehensive interactive system. The microbial 
communities have been studied using 16S ribosomal RNA (rRNA) gene sequencing technology, 
which has been widely used to determine the role of the microbiome in the host’s metabolism, 
physiology development, and resulting disease development.[21]  
The 16S rRNA gene is present in almost all bacterial genomes. 16S rRNA sequencing 
was first used in 1985 for bacterial phylogenetic analysis. It has since become the most widely 
used gene marker in studying bacterial communities. Targeted next-generation sequencing of 
16S rRNA is the first molecular method used to study human microbiota. It results in a 
quantitative description of the bacteria found in biological mixers, and entire biological 
communities and identifies its constituent members.[52]  
The 16S rRNA gene consists of conserved and variable regions.  The sequences of the 
nine hypervariable region (V1-V9) separated by highly conserved regions can provide species-
specific signature information useful for identification of bacteria.  In targeted next-generation 
sequencing of 16S rRNA gene method, the hypervariable region is PCR amplified using 
universal primers targeting conserved regions and sequenced to identify a wide range of existing 
constituent microorganisms.[52] Since V4 was found to have good domain specificity, high 
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coverage, and a broad spectrum in bacteria, targeted sequencing of 16S rRNA V4 region is 
currently widely used in microbiome studies.  
Although mechanisms of chronic immune activation in PWH are not fully understood, 
one mechanism suggested by Brenchley et al contends that disruption of mucosal barriers may 
permit bacterial translocation into the bloodstream in PWH. PWH are known to have elevated 
plasma levels of sCD14, sCD163, and IL-6, which have been linked to increased morbidity and 
mortality of PWH on ART.[10] In humans, the oral cavity has the most abundant microbiomes 
after those found in the gastrointestinal tract. Oral microbiomes have a direct influence on human 
health especially through systemic immune activation.[44] Gao et al reported that interactions of 
well-balanced oral microorganisms help protect the human body from undesirable bacterial and 
viral invasions. Healthy eating and proper oral hygiene are important to keep oral equilibrium in 
a positive state.[44] A number of factors such as diet, the use of tobacco, alcohol consumption, 
poor oral hygiene, and diseases such as diabetes and gingival inflammation can disrupt the 
microbiome balance. In oral cancer patients, most of whom have a history of smoking, the oral 
cavity contained significantly higher amounts of streptococci, Enterococcus, and Pseudomonas 
aeruginosa. Microbiome changes were also observed in periodontitis, severe dental cavities and 
gingivitis.[15]  
 Kistler et al studied the interaction of oral conditions and disease associated pathology in 
PWH. There were differences in the microbiota of the saliva between the HIV positive and HIV 
negative groups. Their findings showed that the microbial diversity was lower in those who were 
HIV+ than those who were HIV-. They also found increased levels of pathogenic bacteria in 
untreated HIV infected individuals compared to the control group.[18] 
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1.3 HIV pathogenesis and herpesvirus activation 
Human herpesvirus infection and reactivation may cause chronic immune activation in 
PWH on ART. HHV infections are usually acquired by close contact with oral secretions during 
early childhood and by sexual activity or blood transfusion later in life. The prevalence of human 
herpesvirus infections is very high in the general population. Most people with normal immune 
systems carry these viruses asymptomatically.[1] If an individual is immunologically 
compromised, such as with untreated HIV infection, then these common viruses can become a 
source of disease. In PWH, there is a greater increase of disease of both infections and cancers 
caused by oncoviruses EBV, HHV-8 and HPV [44]. Verma et al studied the role of viral 
infections that coexist with oral cancers and other systemic diseases, and found that 
immunosuppression caused by HIV infection results in an immune response complicated by 
otherwise tolerable viruses. 
Recently, Agudelo-Hernandez et al reported that herpesvirus shedding rates are higher 
among HIV+ infected men who have sex with men (MSM) despite viral suppression and CD4+ 
T cell reconstitution.[2] The authors showed that PWH on ART in the study had higher rates of 
EBV and CMV shedding as compared to the controls. The level of sCD14 cytokine was 
significantly associated with increased levels of shedding status for EBV. CMV shedding rates 
were not associated with any cytokine biomarkers, but were inversely related to T-cell activation. 
Cytokines IP10 and sCD163 negatively correlated with the HHV6 shedding rates. This suggested 
that reactivation of HHV6 from latency may be driven by lower levels of inflammation. 
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1.3.1  Dynamic changes of oral microbiome in HIV infection 
The microbiome can be assessed by the alpha and beta diversity measurements.[40] 
Alpha diversity is defined as the variety and abundance of organisms in a single community, beta 
diversity is defined as differences in abundance between organisms in different community.[40] 
Decreased microbial diversity and richness in the GI tract have been reported to be correlated 
with increased risk of cardiovascular diseases, certain cancers, and inflammatory diseases.[47] 
The oral cavity harbors a large amount of bacteria that are essential for the development of an 
innate as well as adaptive immune system. Bacterial diversities within the oral cavity can be 
altered at any point with the change of HIV serostatus, and with the chance of acquiring an 
opportunistic infection. PWH have been reported to have a lower alpha diversity of bacteria 
living within their oral cavities.[31]  
Bacterial development in the oral cavity leads to multiple periodontal diseases, but only a 
few harbor the ability to develop and sustain infection. When herpesvirus shedding occurs, a 
bacterial-viral interaction leads to progression of the infection, which not only results in 
periodontitis, but sustains the infection itself.[34] The lesions that reside in the mouth because of 
periodontal infections manifest an elevated level of bacteria. When the herpesvirus is active, the 
systemic immune system, especially the mucosal immunity that resides in the oral cavity, can 
cause localized immune defenses to decrease.[34] Overall, this study suggested that the 
interactions between the oral cavity with both periodontal infection and herpesvirus infection 
coincide with the bacterial diversity in the human mouth. 
 Gianella et. al reported in ART-naïve PWH, there is a positive correlation between 
plasma HIV DNA levels and herpesvirus shedding in blood.  Furthermore, in the PWH on ART, 
over 60% of the cohort had some type of HSV virus. Many of them had higher shedding rates 
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despite being virally suppressed on ART.[11,12] Their study demonstrated that herpesvirus 
shedding was higher among PWH with or without ART compared to seronegative controls. 
Lusso et al developed research methods delving into the correlation between Simian 
immunodeficiency Virus (SIV) with HHV in macaques. The primates infected with SIV showed 
stable CD4+ and CD8+ T cell counts when not inoculated with the HHV6 strain. Once primates 
were superinfected with the HHV6, rapid CD4+ T cell depletion occurred.[22] The coinfection 
results of HHV6 with SIV in primates suggest that similar coinfection of HIV and HHV may 
accelerate the progression to AIDS.[22] After further research, the authors concluded that the 
HHV6 coinfection directly affects the basic pathogenic mechanism of immunodeficiency 
viruses.   
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2.0 Hypothesis and Specific Aims 
2.1 Hypothesis 
Oral microbiome dysbiosis among PWH on ART is associated with higher levels of 
immune activation and systemic inflammation. 
2.2 Specific Objective 
The specific objectives of this study are:  
1. Measurement and analysis of oral microbiome in PWH on ART and age-matched 
HIV negative controls. 
2. Analysis of the oral microbiome profile with oral herpesvirus shedding status and 
soluble markers of inflammation.   
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3.0 Methods 
3.1 Study subjects and sample collection 
Archived frozen samples from 24 participants from the Multicenter-AIDS Cohort study 
(MACS) were used in this study.[2] The MACS is a longitudinal prospective study of MSM. 
Oral wash samples along with blood, semen, urine and stool were collected from 13 HIV (+) 
participants who have been virally suppressed on ART for a median of 7 years and 11 HIV 
uninfected controls at Weeks 0, 4, 8, and 24 of the study. Oral wash samples collected at week 0 
and week 24 were used in this study.  
3.2 DNA isolation from oral wash samples 
DNA was extracted from oral wash samples collected from week 0 and week 24 using 
the Power Soil Extraction kit (Mo Bio, USA) based on the manufacturer’s instruction with minor 
modification. Briefly, 500ul of oral wash sample was dispensed into a tube containing sterile 
beads and vigorously vortexed for 10 minutes. Following multiple washing steps, the DNA was 
eluted from the beads with 100ul of elution buffer and saved in -20C. To control the quality of 
the DNA isolation procedure, positive and negative control tubes were included for each DNA 
isolations run. 
 10 
3.3 Polymerase chain reaction of oral wash samples 
After the completion of the DNA isolation process, PCR was performed on the isolated 
DNA to amplify the hypervariable region (V4) of the bacterial 16S rRNA gene with the 
following primers: 16S Amplicon PCR forward 
Primer=5’TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
:16S Amplicon PCR Barcode tagged Reverse Primer= 
5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC. 
The PCR reaction with total volume of 25ul containing 4ul of extracted DNA was run at 
the following cycling conditions by the Caporaso et. al method. Thermocycle conditions were 
98C for 30s, followed by 25 cycles of 98C for 10s, 57C for 30s, 75C for 30s. After the cycling 
samples were run 72C for 2min, and lastly PCR product was held at 4 degrees. At the completion 
of cycling parameters, 5ul of PCR products were run on a 2% agarose gel to visualize a band 
formation at the 400 base pair mark ensuring that PCR product was amplified for each oral wash 
sample.  
3.4 Clean-up of PCR products  
Following the PCR amplification of bacterial 16S rRNA V4 region, the PCR products 
were cleaned from primers, enzymes and the buffers and selected for 200-600bp using 
SPRIselect for size selection kit (Beckman Coulter) following manufacturer’s protocols. The 
cleaned and size-selected PCR products were stored at -20C for Quantitative analysis by QuBit 
Fluorometer. 
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3.5 Quantitation, pooling, and sequencing of PCR products 
A Qubit Fluorometer can be used for the quantification of DNA, RNA, or protein of a 
sample. After the completion of a PCR clean-up and size-selection, the DNA contents of the 
PCR products were quantitated by a qubit fluorometer using a Broad Range Kit from Life 
Technologies following manufacturer’s instructions. The ideal DNA concentration for 
subsequent pooling procedure is between 2-15 ng/ul. If the DNA concentration of the PCR 
products were lower than 2ng/ul, a PCR would need to be redone on that sample to generate 
more PCR product. The DNA concentration of oral wash samples 5, 13, 29, and 39 was below 2 
ng/ul resulting in a required repetition of PCR. 
The pooling of the cleaned PCR products was performed by combining 40 ng of DNA 
from each sample into one tube. After final clean-up of the pooled DNA using the Purelink PCR 
purification Kit (Life Technologies), the PCR products with PhiX controls were sequenced using 
MiSeq. 
3.6 Bioinformatics analysis of oral wash Sample 
The sequence reads from the respective PCR products were analyzed using Quantitative 
Insights Into Microbial Ecology 2 (QIIME2), the bioinformatics software package for taxonomic 
analysis. Trimming of the sequences was performed in QIIME2 to select the best quality portion 
of each sequence for subsequent analysis. Next, the QIIME2 software, gg-13-8-99-515-806-nb-
classifier was used as a reference base for an operational taxonomic unit (OTUs) assignment for 
the sequence reads. This software developed a baseline taxonomic assignment for oral bacterial 
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composition. The alpha diversity of the bacteria was determined by the Shannon Diversity Index 
method and beta diversity was determined by the use of the Weighted UniFrac method 
implemented by QIIME2. 
3.7 Measurement of herpesvirus shedding rates 
Using the same collected oral samples Macatangay et al and colleagues measured 
herpesvirus shedding in a previous study. Briefly, DNA extraction was performed for all samples 
with EasyMag (bioMerieux, Durham, North Carolina, USA). Following extraction, Real-Time 
Taqman quantitated PCR was performed for quantification of herpesvirus in the samples. Master 
Mix comprised of 5uL sample DNA or control, 10uL of Taqman 2X Gene Expression Master 
Mix (Applied Biosystems, Foster City, California, USA), 1,2 μmol/L forward and reverse 
primers, and 0.3 μmol/L of probe. All samples cycle conditions were: 50ºC for 2 min, 95ºC for 
10 min, followed by 45 cycles of PCR amplification, 95ºC for 15s and 60ºC for 1 min.  
3.8 Measurement of soluble inflammation markers 
In previous study Macatangay et al used commercially available ELISA kits to measure 
soluble inflammation markers sCD14, sCD163, interferon γ-induced protein 10 (IP-10), 
interleukin-6 (IL-6), and C-reactive protein (CRP) following manufacturer’s instructions. 
Inflammation markers were analyzed by using ELX808 ELISA Gen5 software v2.06  (Biotek, 
Winooski, Vermont, USA). 
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3.9 Statistical analysis of oral wash samples 
STATA statistical analysis packages were used for the analysis of the data generated. In 
QIIME2, the Kruskal Wallis Pairwise test was used to examine the difference of alpha diversity 
of oral microbiome based HIV status and/or HHV shedding status. The pairwise Permanova test 
in QIIME2 was used to obtain beta diversity p-values. All p-values were assessed at a confidence 
level of 95% or a p-value ≤ 0.05. P-values at or below 0.05 were considered to be statistically 
significant. A Bonferroni correction for multiple independent observations was applied for the 
shedding status tests. 
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4.0 Results 
4.1 Study Participants 
Table 1 provides specific information regarding the participants of this study. There were 
24 study participants, 13 HIV (+) and 11 HIV (-) with a median age of 41(range=27-50) The 
HIV (+) participants have been infected for a median of 10 years (range=3-19) and had been 
virally suppressed on ART for a median of 7 years (range=1-7). Participants have a median 
CD4+ T cell count of 864 cells/mL  (range=533-1355) 
. 
Table 1. Clinical characteristics of study participants 
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4.2 Oral microbiome sequence and analysis based on results between HIV Status of 
study participants  
The completion of sequencing runs generates the sequence for each sample. Figure 1 
shows the results of sequences reads of the 16S rRNA V4 region of all oral wash samples in this 
study. Along the X-axis, the frequency reads per sample is compared to the Y-axis alignment 
demonstrating the number of samples at a given frequency. 
The sequence read frequencies ranged from a low of 34,201 counts/sample to a high of 
85,379 counts/sample, with an average of 49,413 counts/sample (Table 2). These results indicate 
that even the lowest counts (34,291 counts/sample), using the standard of 30,000 counts/sample 
as an acceptable norm (Caporaso et al), provided sufficient sequence counts for the subsequent 
sequence analysis.  
 
 
Figure 1 Quality score and parameters of sequences Generated 
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Table 2 Summary table of microbiome sequencing run 
 
Taxonomy plots generated from sequence analysis using QIIME provide a general 
overview of bacterial species richness in each oral wash sample (Figure 2). The samples were 
categorized by HIV status and compared the relative frequency in percentages (%) of the amount 
of each bacterium present at the family level in each analyzed sample. It is evident that there is a 
wide variety of bacterial content across the samples. The top four phyla were Bacteroidetes, 
Firmicutes, Actinobacteria, and Proteobacteria. There was no apparent difference in the ranges of 
bacteria across samples between the two study groups.  
 
 
Figure 2 Taxonomy plot at the family level 
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Sequence analysis also generates alpha and beta diversity based on varieties of bacterial 
species contained in the samples. Alpha diversity is defined as the bacterial species richness in a 
given sample. Beta diversity is defined as the similarity or dissimilarity between multiple 
samples measured by Weighted UniFrac Significance. 
Using STATA software, box plots were generated based on three variables, the alpha 
diversity of each sample generated by Shannon Diversity Index method, week of sample 
collection, and HIV status. Figure 3A demonstrates a comparison of the alpha diversity at the 
beginning of the study, week 0and that at week 24. There were no significant differences in the 
alpha diversity between the two time points (week 0 and 24; p=0.75) suggesting no changes in 
the oral bacterial diversity within the 24 week period. Similarly, no differences in the alpha 
diversity were observed between HIV infected participants and uninfected controls (p=0.18) 
In figure 3C the levels of alpha diversity were further analyzed based on HIV status, and 
the sample time points of week 0 and week 24. There were no statistical differences of alpha 
diversity between HIV+ and HIV- groups at both time points. Between the same time points 
although there appears to be higher level of alpha diversity in the HIV + group, this did not reach 
statistical significance. 
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Figure 3 Comparison of Alpha diversity in HIV-infected and HIV-uninfected groups  
 
 Principal Component Analysis is used to reduce large amounts of data into a three-
dimensional space. Data points similar to each other will cluster closer together. Bray Curtis 
plots based on beta diversity by Weighted UniFrac method in QIIME2 were generated to define 
the difference in microbial composition between samples (Figure 4). Axis 1, 2, and 3 showed the 
percent of variance between the samples that is explained by the first three principal components 
respectively. In figure 4A beta diversity was generated based on HIV status. Figure 4B shows the 
beta diversity between samples based on the week of sample collection. Lastly, Figure 4C shows 
beta diversity based both on HIV statuses and sample collection time points. However, there are 
no significant differences between the beta diversities based on a Pairwise Permanova test with 
all p-values >0.05 from Figure 4. 
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Figure 4 Bray-Curtis PCA plot of oral wash samples 
4.3 Analysis of oral bacterial alpha diversity with HHV shedding status and 
cytokine levels 
In a previous study, multiple human herpesviruses such as HHV6, HHV8, EBV, and 
CMV were measured in the oral wash samples which were regarded as shedding negative if no 
virus was detected or shedding positive if the virus was detected. In figure 5A, B, C and D, levels 
of alpha diversity were compared based on HHV6, HHV8, EBV or CMV shedding statuses at 
week 0 and week 24.  
The alpha diversity of each sample was further evaluated based on herpesvirus shedding 
status to assess the effects of a herpesvirus shedding on oral microbiome (Figure 5). The results 
show there were significantly lower alpha diversities in HHV6 shedding samples compared to no 
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HHV6 shedding samples with a p value of 0.009 regardless of HIV infection status. To confirm, 
Bonferroni Correction was applied generating a p=0.0125 resulting statistical significance of 
HHV6 shedding status. Similarly, alpha diversities were also analyzed based on the shedding 
statuses of HHV8, EBV and CMV.  There are no statistical differences of alpha diversities based 
on HHV8 shedding status (p=0.29), EBV shedding status (p=0.57), and CMV shedding status 
(p=0.49) at the 95% CI. 
. 
 
Figure 5 Alpha diversity compared to HHV status with week of sample collection 
 
Beta diversity of oral bacteria was also analyzed based on HHV shedding status (Figure 
6). In figure 6A beta diversity was analyzed based on HHV6 status. There is significant 
difference in beta diversity between HHV6 shedding samples and no HHV6 shedding samples 
with p=0.008. Bonferroni Correction was applied generating a p=0.0125 confirming statistical 
significance of HHV6 shedding status. Figure 6B, 6C and 6D demonstrate the beta diversity 
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based on sample’s HHV8, EBV or CMV shedding status. There are no statistical differences in 
beta diversity based on HHV8, CMV, or EBV shedding statuses. 
 
 
Figure 6 Bray-Curtis PCA plot comparisons between HHV statuses 
 
From the previous study with the same study participants, five soluble markers: IP10, IL-
6, sCD14, sCD163, and CRP of inflammation with were measured in plasma to determine the 
inflammatory cytokine levels at each time point.[2] Multivariate correlation analysis of alpha 
diversity of oral bacteria and the cytokine levels were performed and no significant correlations 
were observed between bacterial diversity and plasma levels of the different soluble markers.  
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5.0 Discussion 
The goal of this study was to determine whether oral microbiome dysbiosis among PWH 
on ART is associated with higher levels of immune activation and systemic inflammation. 
Persistent inflammation and chronic immune activation result from HIV (+) infection. Metabolic 
changes in PWH associated with impairment of the immune system resulting in cytokine 
network changes results in inflammation in both ART treated and untreated individuals.[46] 
Altered immune system status could lead to non-AIDS diseases in PWH according to Zicari et al. 
Those non-AIDS diseases include cancers and HIV-associated lipodystrophy syndrome (HALS) 
characterized by redistributed body fat and adipose tissue damage. The presence of this condition 
makes these individuals have an elevated cardiovascular risk. 
As all adults age, there are documented declines in physical function and the onset of 
frailty. These are closely associated with inflammation and immune system dysfunction. Among 
aging PWH there are earlier declines in physical function and developing frailty. Erlandson et al 
describes three levels of decline; normal aging declines, moderate declines among PWH on 
ART, and the most severe among PWH not receiving ART. The status of immune activation is 
best controlled with ART among those who have high CD4+ T-cell counts. Hileman et al 
proposed ART is effective in reducing persistent inflammation and immune activation but not to 
the level found in HIV (–) people. 
There are different microbial communities in different human body parts due to vastly 
different conditions on our skin and in our mouths, noses, and guts. The oral microbiome 
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detected from our study participants was mainly composed of five major phyla (Figure 2): 
Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, and Fusobacteria, which are consistent 
with the findings of numerous previous studies.[10,29,35] 
HIV infections are known to influence alterations in both the gut and oral microbiome 
due to its systemic effects on mucosal surfaces.[29] Also McHardy et al showed that PWH have 
an altered bacterial richness in both gut and oral mucosa due to the infection. The McHardy et al 
study also concluded that participants who were virally suppressed on ART treatment had similar 
bacterial species richness compared to uninfected individuals. As a result, the use of ART may 
be considered an effective mechanism for maintaining a healthy gut or oral microbiome 
composition.  We measured oral microbiome through the 24-week-study period in both PWH on 
ART and control individuals. The taxonomy plot (Figure 2) showing the different bacteria at 
family level displays the similar microbiome profile in both populations at both sample 
collection dates, which indicates that overall trend of bacterial diversity and richness was similar 
between PWH on ART and uninfected controls and was fairly stable in all participants over the 
24-week-study period. 
There are two parameters frequently used in microbiome analysis: alpha diversity and 
beta diversity of the bacterial species composition.  Both the alpha diversity and beta diversity 
can be largely impacted by the disturbance of the microbiome due to any factors limiting the 
range of optimization for the community.[37] Alpha diversity is defined as the variety and 
abundance of organisms in a community or sample; Beta diversity is defined as measuring the 
similarity or dissimilarity between multiple communities or samples.[45] Our results showed that 
there is an increase of alpha diversity in PWH on ART group compared to uninfected controls at 
both week 0 and week 24 time points. However, this increase was not statistically significant. 
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Currently, it is not clear whether this difference is due to the sample variation or limited sample 
size in this study. Future study with larger sample size is needed to confirm this difference. 
All herpesviruses lead to life-long latent infection with periodical reactivation depending 
on various local and systemic conditions including HIV infection. Oral herpesvirus infection and 
reactivation are mostly asymptomatic, which however could disrupt oral microbiome 
environment and lead to microbiome dysbiosis. Our study showed that alpha diversity levels 
significantly decreased in participants who were orally shedding HHV 6 compared to the 
subjects who were not orally shedding HHV6 at both at week 0 and week 24 time points. 
Furthermore, we show that there is significant difference of beta diversity in the participants 
orally shedding of HHV6 compared to the participants who were not orally shedding HHV6. 
There are no significant differences in alpha and beta diversities of oral microbiome when 
analyzed based on other herpesvirus (HHV8, CMV, and EBV) oral-shedding statuses.  
Herpesvirus also potentially affects the progression of Alzheimer’s disease (AD). The most 
common cause of dementia is Alzheimer’s and evolving research has indicated most studies have 
shown the association of HHV for AD.[7] Herpesviruses have the ability to become latent in the 
host and later infect neurons. Studies show HHV6 had a 23% positivity in blood samples from 
Alzheimer’s disease infected individuals. 17% of AD brains were HHV6 positive in the Carbone 
et al study. This indicates that continued research should be conducted as findings suggest that 
HHV6 poses a significant risk factor for cognitive dysfunction and may lead to AD in the 
elderly.  Factors to study include viral latency to help clarify the role of HHV6 pathogen in AD.  
In a previous study, plasma cytokine markers IL-6, CRP, sCD4, sCD163, and IP-10 were 
measured in the same study participants at the same study visits.[2] Therefore, we examined the 
relationship of levels of soluble markers of inflammation to levels of alpha diversity to 
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investigate the role of oral microbiome in systemic immune activation. Interestingly, there were 
no significant correlations observed among the soluble markers and alpha diversity. These 
soluble markers have been associated with persistent immune activation among treated 
PWH.[18] Previous studies indicate a possible association of continued immune activation as the 
result of replication of HIV in latent reservoirs. The Gianella et al study found that more than 
75% of PWH on ART had at least one actively replicating HIV in their mucosal tissue.  This 
study aligning with our results suggests that HIV replication may be a potential cause of chronic 
immune activation levels.[16]  
There are multiple limitations that exist in this study that could be affecting the results of 
the project. First, data was obtained from a small study population (N=23) so results may not be 
generalizable to all PWH on ART. Similarly, the study only includes MSM. Results from women 
infected with HIV on ART should also be assessed to see whether findings would be consistent 
with different study populations. Third, we did not monitor the dietary intake and oral hygiene of 
participants. Previous studies concluded that eating, drinking, and smoking constitute varying 
factors affecting the oral microbiome of any individual whether the person is HIV infected or 
HIV uninfected.[39]  
Our conclusions did not support our original hypothesis that the oral microbiome 
dysbiosis of PWH on ART is associated with immune activation and inflammation. Further 
research is indicated to clarify the discrepancy between the findings of our study and those of 
previous researchers. 
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6.0 Public Health Significance 
Advances in ART have increased the overall life expectancy for PWH. Even with viral 
suppression on ART, PWH still have persistent immune activation and elevated levels of 
inflammation compared to HIV-uninfected individuals. The incidence of HIV and related 
diseases continues to be significant on an international basis. According to WHO, there are 
presently nearly 37 million people throughout the world living with HIV. A major aspect of this 
is the huge demand for specific treatment and a simultaneously critical need for prevention and 
continuing research.  
Studying the microbiomes in the human body, and how shedding effects may cause 
systemic complications, research is vital considering the magnitude of the public health concern 
of HIV infections. Immune activation that results from associated microbiome dysbiosis presents 
a significant effect resulting from the co-infection and comorbidity of the two conditions. 
Additionally, there is a significant economic impact of this widespread disorder and the systemic 
diseases that are associated with HIV. Studies of microbiomes have raised the level of alertness 
of the importance and impact that they have on the health of infected humans. The role of 
microbiomes in the co-infection process of herpes shedding and HIV indicates the strong need 
for research, prevention, and effective therapeutic interventions to be developed and 
implemented. 
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